Disc Medicine, Inc. (NASDAQ:IRON) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of Disc Medicine, Inc. (NASDAQ:IRON) have received an average recommendation of “Moderate Buy” from the fourteen brokerages that are covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and twelve have assigned a buy recommendation to the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $119.4545.

Several equities analysts have recently issued reports on the company. UBS Group reissued an “overweight” rating on shares of Disc Medicine in a report on Thursday, January 15th. National Bankshares set a $153.00 price target on Disc Medicine in a report on Friday, October 17th. Wells Fargo & Company raised their price objective on shares of Disc Medicine from $91.00 to $109.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 16th. Cowen reaffirmed a “buy” rating on shares of Disc Medicine in a report on Friday, December 19th. Finally, Truist Financial increased their price target on shares of Disc Medicine from $86.00 to $114.00 and gave the stock a “buy” rating in a report on Monday, November 10th.

Disc Medicine Stock Up 4.3%

IRON stock opened at $74.00 on Wednesday. The company has a market capitalization of $2.79 billion, a P/E ratio of -13.83 and a beta of 0.87. Disc Medicine has a 12 month low of $30.82 and a 12 month high of $99.50. The firm’s fifty day simple moving average is $85.06 and its 200-day simple moving average is $72.95. The company has a debt-to-equity ratio of 0.05, a current ratio of 23.45 and a quick ratio of 23.45.

Disc Medicine (NASDAQ:IRON) last posted its earnings results on Thursday, November 6th. The company reported ($1.77) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.48) by ($0.29). As a group, equities research analysts forecast that Disc Medicine will post -4.07 earnings per share for the current year.

Insiders Place Their Bets

In other news, COO Jonathan Yen-Wen Yu sold 30,000 shares of the stock in a transaction dated Tuesday, November 11th. The shares were sold at an average price of $84.70, for a total transaction of $2,541,000.00. Following the sale, the chief operating officer directly owned 40,555 shares of the company’s stock, valued at $3,435,008.50. This represents a 42.52% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Rahul Khara sold 6,500 shares of Disc Medicine stock in a transaction dated Friday, January 2nd. The shares were sold at an average price of $78.69, for a total value of $511,485.00. Following the completion of the transaction, the insider owned 37,793 shares of the company’s stock, valued at approximately $2,973,931.17. This represents a 14.68% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 274,470 shares of company stock valued at $24,896,430. Insiders own 3.64% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in IRON. Aster Capital Management DIFC Ltd purchased a new stake in Disc Medicine in the 3rd quarter worth $38,000. CWM LLC lifted its holdings in Disc Medicine by 213.5% during the second quarter. CWM LLC now owns 1,044 shares of the company’s stock valued at $55,000 after purchasing an additional 711 shares in the last quarter. Avanza Fonder AB acquired a new stake in shares of Disc Medicine in the second quarter valued at about $57,000. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Disc Medicine by 15.6% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,338 shares of the company’s stock worth $71,000 after purchasing an additional 181 shares in the last quarter. Finally, Russell Investments Group Ltd. increased its stake in shares of Disc Medicine by 15,137.5% during the third quarter. Russell Investments Group Ltd. now owns 2,438 shares of the company’s stock worth $161,000 after purchasing an additional 2,422 shares in the last quarter. Hedge funds and other institutional investors own 83.70% of the company’s stock.

Disc Medicine Company Profile

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.